Boehringer Ingelheim's Ofev nabs FDA nod for expanded use in rare lung disease

Boehringer Ingelheim cast a wide net with its clinical program for pulmonary fibrosis med Ofev, hoping to carve out a sales niche in a huge range of ultra-rare lung diseases. Already sporting an FDA nod in one subclass, Ofev can now target an even larger patient pool with its newest approval.